Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures

Journal of Neurochemistry

Volumn 91, Issue 6, 2004, Pages 1358-1368

  Zhang, Lixin ^a   Fletcher Turner, Anita ^b   Marchionni, Mark A ^c   Apparsundaram, Subbu ^a   Lundgren, Kerstin H ^d   Yurek, David M ^b   Seroogy, Kim B ^a,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c CeNeS Pharmaceuticals plc   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine; Glial growth factor; Glial growth factor 2; Neuroprotection; Neurotrophic factor; Parkinson's disease

Indexed keywords

CATECHOLAMINE; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL GROWTH FACTOR 2; NEU DIFFERENTIATION FACTOR; NEURITE PROMOTING FACTOR; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; EMBRYO; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; MESENCEPHALON; NERVE CELL CULTURE; NERVE FIBER GROWTH; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DOPAMINE; EMBRYO; HUMANS; MESENCEPHALON; NERVE TISSUE PROTEINS; NEURITES; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 7044253710     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02817.x     Document Type: Article

References (65)

1. Adlkofer K. and Lai C. (2000) Role of neuregulins in glial cell development. Glia 29, 104-111.
2. Altar C. A., Boylan C. B., Jackson C., Hershenson S., Miller J., Wiegand S. J., Lindsay R. M. and Hyman C. (1992) Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl Acad. Sci. USA 89, 11 347-11 351.
3. Apparsundaram S., Schroeter S., Giovanetti E. and Blakely R. D. (1998) Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287, 744-751.
4. Bermingham-McDonogh O., McCabe K. L. and Reh T. A. (1996) Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina. Development 122, 1427-1438.
5. Bermingham-McDonogh O., Xu Y. T., Marchionni M. A. and Scherer S. S. (1997) Neuregulin expression in PNS neurons: isoforms and regulation by target interactions. Mol. Cell. Neurosci. 10, 184-195.
6. Bilsland J., Roy S., Xanthoudakis S., Nicholson D. W., Han Y., Grimm E., Hefti F. and Harper S. J. (2002) Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J. Neurosci. 22, 2637-2649.
7. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. and Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
8. Burden S. and Yarden Y. (1997) Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18, 847-855.
9. Calaora V., Rogister B., Bismuth K., Murray K., Brandt H., Leprince P., Marchionni M. and Dubois-Dalcq M. (2001) Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. J. Neurosci. 21, 4740-4751.
10. Cannella B., Pitt D., Marchionni M. and Raine C. S. (1999) Neuregulin and erbB receptor expression in normal and diseased human white matter. J. Neuroimmunol. 100, 233-242.
11. Canoll P. D., Musacchio J. M., Hardy R., Reynolds R., Marchionni M. A. and Salzer J. L. (1996) GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17, 229-243.
12. Collier T. J. and Sortwell C. E. (1999) Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14, 261-287.
13. Dong Z., Brennan A., Liu N., Yarden Y., Lefkowitz G., Mirsky R. and Jessen K. R. (1995) Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron 15, 585-596.
14. Eggert K., Schlegel J., Oertel W., Wurz C., Krieg J. C. and Vedder H. (1999) Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci. Lett. 269, 178-182.
15. Engele J., Schubert D. and Bohn M. C. (1991) Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: role of mesencephalic glia. J. Neurosci. Res. 30, 359-371.
16. Erlich S., Goldshmit Y., Lupowitz Z. and Pinkas-Kramarski R. (2001) ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience 107, 353-362.
17. Falls D. L. (2003) Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284, 14-30.
18. Gassmann M. and Lemke G. (1997) Neuregulins and neuregulin receptors in neural development. Curr. Opin. Neurobiol. 7, 87-92.
19. Gerecke K. M., Wyss J. M., Karavanova I., Buonanno A. and Carroll S. L. (2001) ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J. Comp. Neurol. 433, 86-100.
20. Goldshmit Y, Erlich S. and Pinkas-Kramarski R. (2001) Neuregulin rescues PC12-ErbB4 cells from cell death induced by H(2)O(2). Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J. Biol. Chem. 276, 46 379-46 385.
21. Grunblatt E., Mandel S. and Youdim M. B. (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol. 247 (suppl. 2), II95-II102.
22. Guo X., Dawson V. L. and Dawson T. M. (2001) Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur. J. Neurosci. 13, 1683-1693.
23. Hou J. G., Cohen G. and Mytilineou C. (1997) Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system. J. Neurochem. 69, 76-83.
24. Knusel B., Beck K. D., Winslow J. W., Rosenthal A., Burton L. E., Widmer H. R., Nikolics K. and Hefti F. (1992) Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J. Neurosci. 12, 4391-4402.
25. Kordower J. H., Emborg M. E., Bloch J, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
26. Kornblum H. I., Yanni D. S., Easterday M. C. and Seroogy K. B. (2000) Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. Dev. Neurosci. 22, 16-24.
27. Kramer B. C., Goldman A. D. and Mytilineou C. (1999) Glial cell line derived neurotrophic factor promotes the recovery of dopamine neurons damaged by 6-hydroxydopamine in vitro. Brain Res. 851, 221-227.
28. Krane I. M. and Leder P. (1996) NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12, 1781-1788.
29. Li B. S., Ma W., Jaffe H., Zheng Y., Takahashi S., Zhang L., Kulkarni A. B. and Pant H. C. (2003) Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem. 278, 35 702-35 709.
30. Lindsay R. M., Altar C. A., Cedarbaum J. M., Hyman C. and Wiegand S. J. (1993) The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124, 103-118.
31. Marchionni M. A., Cannella B., Hoban C. et al. (1999) Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. Adv. Exp. Med. Biol. 468, 283-295.
32. Mena M. A., de Bernardo S., Casarejos M. J., Canals S. and Rodriguez-Martin E. (2002) The role of astroglia on the survival of dopamine neurons. Mol. Neurobiol. 25, 245-263.
33. Meyer D. and Birchmeier C. (1994) Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc. Natl Acad. Sci. USA 91, 1064-1068.
34. Michel P. P. and Hefti F. (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26, 428-435.
35. Moller J. C., Sautter J. and Kupsch A. (1996) Potential of neurotrophic factors in therapy of Parkinson's disease. J. Neural Transm. Suppl. 48, 103-112.
36. Numan S. and Seroogy K. B. (1997) Increased expression of trkB mRNA in rat caudate-putamen following 6-OHDA lesions of the nigrostriatal pathway. Eur. J. Neurosci. 9, 489-495.
37. O'Malley E. K., Black I. B. and Dreyfus C. F. (1991) Local support cells promote survival of substantia nigra dopaminergic neurons in culture. Exp. Neurol. 112, 40-48.
38. O'Malley E. K., Sieber B. A., Black I. B. and Dreyfus C. F. (1992) Mesencephalic type I astrocytes mediate the survival of substantia nigra dopaminergic neurons in culture. Brain Res. 582, 65-70.
39. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Lanciego J. L., Artieda J., Gonzalo N. and Olanow C. W. (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23, S8-S19.
40. Parker M. W., Chen Y., Hallenbeck J. M. and Ford B. D. (2002) Neuregulin expression after focal stroke in the rat. Neurosci. Lett. 334, 169-172.
41. Pinkas-Kramarski R., Eilam R., Spiegler O., Lavi S., Liu N., Chang D., Wen D., Schwartz M. and Yarden Y. (1994) Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. Proc. Natl Acad. Sci. USA 91, 9387-9391.
42. Raabe T. D., Francis A. and DeVries G. H. (1998) Neuregulins in glial cells. Neurochem. Res. 23, 311-318.
43. Rieff H. I., Raetzman L. T., Sapp D. W., Yeh H. H., Siegel R. E. and Corfas G. (1999) Neuregulin induces GABA(A) receptor subunit expression and neurite outgrowth in cerebellar granule cells. J. Neurosci. 19, 10 757-10 766.
44. Rio C., Rieff H. I., Qi P., Khurana T. S. and Corfas G. (1997) Neuregulin and erbB receptors play a critical role in neuronal migration. Neuron 19, 39-50.
45. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H. S. and Björklund A. (1999) Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11, 1554-1566.
46. Rosenblad C., Kirik D. and Björklund A. (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161, 503-516.
47. Sortwell C. E., Daley B. F., Pitzer M. R., McGuire S. O., Sladek J. R. Jr and Collier T. J. (2000) Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J. Comp. Neurol. 426, 143-153.
48. Specht L. A., Pickel V. M., Joh T. H. and Reis D. J. (1981) Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. II. Late ontogeny. J. Comp. Neurol. 199, 255-276.
49. Spina M. B., Hyman C., Squinto S. and Lindsay R. M. (1992a) Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann. N. Y. Acad. Sci. 648, 348-350.
50. Spina M. B., Squinto S. P., Miller J., Lindsay R. M. and Hyman C. (1992b) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59, 99-106.
51. Stefansson H., Sigurdsson E., Steinthorsdottir V. et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892.
52. Steiner H., Blum M., Kitai S. T. and Fedi P. (1999) Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. Exp. Neurol. 159, 494-503.
53. Takeshima T., Johnston J. M. and Commissiong J. W. (1994a) Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. J. Neurosci. 14, 4769-4779.
54. Takeshima T., Johnston J. M. and Commissiong J. W. (1994b) Oligodendrocyte-type-2 astrocyte (O-2A) progenitors increase the survival of rat mesencephalic, dopaminergic neurons from death induced by serum deprivation. Neurosci. Lett. 166, 178-182.
55. Takeshima T., Shimoda K., Johnston J. M. and Commissiong J. W. (1996) Standardized methods to bioassay neurotrophic factors for dopaminergic neurons. J. Neurosci. Meth. 67, 27-41.
56. Teismann P., Tieu K., Cohen O., Choi D. K., Wu du C., Marks D., Vila M., Jackson-Lewis V. and Przedborski S. (2003) Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18, 121-129.
57. Tokita Y., Keino H., Matsui F., Aono S., Ishiguro H., Higashiyama S. and Oohira A. (2001) Regulation of neuregulin expression in the injured rat brain and cultured astrocytes. J. Neurosci. 21, 1257-1264.
58. Vaskovsky A., Lupowitz Z., Erlich S. and Pinkas-Kramarski R. (2000) ErbB-4 activation promotes neurite outgrowth in PC12 cells. J. Neurochem. 74, 979-987.
59. Vila M., Jackson-Lewis V., Guegan C., Wu D. C., Teismann P., Choi D. K., Tieu K. and Przedborski S. (2001) The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14, 483-489.
60. Villegas R., Villegas G. M., Longart M., Hernandez M., Maqueira B., Buonanno A., Garcia R. and Castillo C. (2000) Neuregulin found in cultured-sciatic nerve conditioned medium causes neuronal differentiation of PC12 cells. Brain Res. 852, 305-318.
61. Voorn P., Kalsbeek A., Jorritsma-Byham B. and Groenewegen H. J. (1988) The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 25, 857-887.
62. Yarden Y. and Sliwkowski M. X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137.
63. Yurek D. M. and Seroogy K. B. (2001) Neurotrophic factor protection of dopaminergic neurons, in Neurobiology of the Neurotrophins (I. Mocchetti, ed.), pp. 355-397. F. P. Graham Publishing, Johnson City, TN, USA.
64. Zhang L., Dhillon H. S., Barron S., Hicks R. R., Prasad R. M. and Seroogy K. B. (2000) Effects of chronic ethanol administration on expression of BDNF and trkB mRNAs in rat hippocampus after experimental brain injury. Brain Res. Mol. Brain Res. 79, 174-179.
65. Zhao J. J. and Lemke G. (1998) Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes. Development 125, 1899-1907.